Probiodrug will provide research funding to the laboratory of Cynthia Ann Lemere in the Center for Neurologic Diseases at Brigham and Women’s Hospital, a teaching hospital affiliated with Harvard Medical School. Dr. Lemere is pioneering immunotherapy approaches to eliminate pyroglutamated (pGlu) Abeta, a highly toxic peptide that has been linked to the progression of Alzheimer’s disease.
By providing funding to Dr. Lemere, Probiodrug has extended a long-standing collaboration with Brigham and Women’s Hospital that began in 2008. In the initial stage of the collaboration, Probiodrug scientists and Dr. Lemere worked to characterize the deposition of pGlu Abeta in different animal models with Alzheimer’s-like pathology and in the human brain. Based on this research, the German biotech developed an anti-pGlu Abeta monoclonal antibody that was shown in transgenic pre-clinical models to significantly reduce the concentration of plaque deposits in the hippocampus and cerebellum that is characteristic of Alzheimer’s disease progression.
Probiodrug’s new funding will be used to expand Dr. Lemere’s work to include additional research aimed at understanding mechanisms of clearance using several experimental anti-pGlu Abeta monoclonal antibodies also provided by the German company. Both partners hope to advance the understanding of how the removal of pGlu Abeta may stop the progression of Alzheimer’s disease.
With this collaboration, Probiodrug is betting on basic research, so important but often forgotten by both, pharmas and states. By gaining a better understanding of Alzheimer’s pathology, the company might be able to develop innovative therapies against this terrible disease.